Loading…
← CockpitCompetitor Analysis › DRREDDY.NS Dr. Reddy's LaboratoriesOpen in the cockpit ↗

Dr. Reddy's LaboratoriesDRREDDY.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Major Indian generic-drug maker selling generics, APIs and biosimilars across the US, Europe, Russia/CIS and India.

≈ India's Teva PharmaceuticalMomentum leader 80
Mkt cap
$12.5B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$29.6M
20-day average traded
Fwd P/E
32.0×
forward earnings
ROIC−WACC
-4.5 pp
WACC 10.1%
Hurdle
+19 pp
Req g minus delivered
Next earnings
65 days
22 Jan 2027
Close · INR₹1,398
1D+0.7%
1W+1.5%
1M+12.5%
3M+18.6%
6M+4.7%
YTD+10.0%
1Y+13.7%
ATR %1.8%
Beta0.45
52w lowhigh1.2% off high

What Dr. Reddy's Laboratories does

Major Indian generic-drug maker selling generics, APIs and biosimilars across the US, Europe, Russia/CIS and India.

North America, mainly generics sold to wholesalers, pharmacy chains and purchasing groups, is the largest region, and profit swings come from a few limited-competition generic launches, since prices on older products fall as competitors enter. Active ingredients sold to other drugmakers add a smaller line. The Reddy family and associates are the promoters.

In one line: India's Teva Pharmaceutical.

Products and services

  • US generics
  • India branded formulations
  • Russia/CIS generics
  • APIs (active pharma ingredients)
  • Biosimilars

Customers

  • US pharmacy chains/PBMs
  • Hospitals and distributors (Russia/CIS)
  • Indian retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • API manufacturing
  • Global generics + biosimilars

What could go right

  • US generic launches (limited-competition drugs)
  • Biosimilar approvals

What could go wrong

  • US generic price erosion
  • FDA plant inspection risk

Moat: narrow (scale, regulatory licence, distribution). Large vertically integrated API-to-formulation manufacturing and broad regulatory filings.

Headquarters: Hyderabad, India · Founded: 1984 · Employees: 27,527

Named competitors

Dr. Reddy's Laboratories at a glance

Size Dr. Reddy's Laboratories (DRREDDY.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $12.5B, the 94th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,398 on 18 Nov 2026.

Performance Over six months the shares gained 4.7%, against +8.3% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 3.6% over the last twelve months (peer median +14.6%); the operating margin is 8.9% (peer median 21.5%).

Valuation It trades at 32.0× forward earnings against a peer median of 27.6× (8th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.5 points below its cost of capital (10.1% WACC).

Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 109DRREDDY.NS 106
Six months, rebased to 100: Dr. Reddy's Laboratories against the median of its 20 peers (local-currency closes).

Dr. Reddy's Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹330B₹336B₹326B₹279B₹246B
Revenue growth—+3%+17%+14%—
Gross profit₹151B₹165B₹180B₹156B₹133B
EBITDA₹50.8B₹67.4B₹86.6B₹78.7B₹64.9B
Net income₹28.0B₹42.9B₹56.5B₹55.7B₹45.1B
Free cash flow₹11.7B₹30.5B₹18.8B₹28.5B₹46.5B
Capital expenditure₹26.2B₹38.4B₹34.4B₹27.4B₹18.9B
Total debt₹72.3B₹77.3B₹46.8B₹20.0B₹13.5B

Quarterly statements and history in the cockpit →

Dr. Reddy's Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%1177ZYDUSLIFE6990REC600436MANKINDLAURUSLABSRGENIPN6885060005386446TGTXORNAV300759JAZZSOBISYREEXELMDGLDRREDDY.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Dr. Reddy's Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×1177ZYDUSLIFE6990REC600436LAURUSLABS6446TGTXORNAVMDGLDRREDDY.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dr. Reddy's Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%+400%0%200%400%11776990REC6004366446TGTXDRREDDY.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dr. Reddy's Laboratories is the large dot.

Dr. Reddy's Laboratories competitors and peer comparison

Head to head with its named competitors (DRREDDY.NS vs SUNPHARMA.NS vs CIPLA.NS vs LUPIN.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%32.0×30.7%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%

How Dr. Reddy's Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dr. Reddy's Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureDRREDDY.NSPeer medianRank in peer set
1-month return+12.5%+5.7%5th highest of 21
6-month return+4.7%+8.3%9th lowest of 21
Distance from 52-week high-1.2%-7.2%highest of 21
Revenue growth (TTM)-3.6%+14.6%2nd lowest of 20
Operating margin8.9%21.5%5th lowest of 20
Forward P/E32.0×27.6×8th most expensive of 19
Growth the price implies (Req g, 7 yrs)30.7%1.1%5th most demanding of 16
Growth delivered (Del g)+12.1%+12.6%7th lowest of 16
Hurdle (Req g minus delivered)+18.6 pp-11.4 pp4th most demanding of 16
ROIC minus cost of capital-4.5 pp+5.6 pp4th lowest of 19
EV / EBITDA22.9×16.0×6th most expensive of 14
Net debt / EBITDA-0.1×0.7×6th least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a

Questions

Who are Dr. Reddy's Laboratories's main competitors?
Named competitors: Sun Pharmaceutical (SUNPHARMA.NS), Cipla (CIPLA.NS), Lupin (LUPIN.NS), Teva Pharmaceutical (TEVA), Viatris (VTRS). The cockpit's measured peer set (industry) also includes Sbp (1177.HK), Zydus Lifesciences (ZYDUSLIFE.NS), Sichuan Kelun-Biotech Biopharmaceutical (6990.HK), Recordati (REC.MI), Zhangzhou Pientzehuang Pharmaceutical (600436.SS), Mankind Pharma (MANKIND.NS).
Is Dr. Reddy's Laboratories expensive compared with its peers?
On forward p/e it trades at 32.0× against a peer median of 27.6×, 8th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Dr. Reddy's Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +4.7% against +8.3% for the median peer; over one year +13.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.